Oklahoma 2022 Regular Session

Oklahoma Senate Bill SB1152 Compare Versions

Version 1 (Old)

Version 2 (New)

Old	New		Differences
1	1
2	2
	3	+	SB1152 HFLR Page 1
	4	+	BOLD FACE denotes Committee Amendments. 1
	5	+	2
	6	+	3
	7	+	4
	8	+	5
	9	+	6
	10	+	7
	11	+	8
	12	+	9
	13	+	10
	14	+	11
	15	+	12
	16	+	13
	17	+	14
	18	+	15
	19	+	16
	20	+	17
	21	+	18
	22	+	19
	23	+	20
	24	+	21
	25	+	22
	26	+	23
	27	+	24
3	28
4		-	An Act
5		-	ENROLLED SENATE
	29	+	HOUSE OF REPRESENTATIVES - FLOOR VERSION
	30	+
	31	+	STATE OF OKLAHOMA
	32	+
	33	+	2nd Session of the 58th Legislature (2022)
	34	+
	35	+	ENGROSSED SENATE
6	36		BILL NO. 1152 By: Standridge of the Senate
7	37
8	38		and
9	39
10	40		Worthen of the House
11	41
12	42
13	43
14	44
15	45		An Act relating to the Uniform Controlled Dangerous
16	46		Substances Act; amending 63 O. S. 2021, Section 2-204,
17	47		which relates to Schedule I ; modifying inclusions;
18	48		and providing an effective date .
19	49
20	50
21	51
22	52
23		-	SUBJECT: Modifying inclusions of Schedule I controlled substances
24		-
25	53		BE IT ENACTED BY THE PEOPLE OF THE STATE OF OKLAHOMA:
26		-
27	54		SECTION 1. AMENDATORY 63 O.S. 2021, Section 2-204, is
28	55		amended to read as follows:
29		-
30	56		Section 2-204. The controlled substances l isted in this section
31	57		are included in Schedule I and include any material, compound,
32	58		mixture or preparation that contains any quan tity of the following
33	59		hallucinogenic substances, their salts, isomers and salts of
34	60		isomers, unless specifically excepted, when the existence of these
35	61		salts, isomers and salts of isomers is possible within the specific
36	62		chemical designation.
37		-
38	63		A. Any of the following opiates, including their isom ers,
39	64		esters, ethers, salts, and salts of isomers, esters, a nd ethers,
	65	+
	66	+	SB1152 HFLR Page 2
	67	+	BOLD FACE denotes Committee Amendments. 1
	68	+	2
	69	+	3
	70	+	4
	71	+	5
	72	+	6
	73	+	7
	74	+	8
	75	+	9
	76	+	10
	77	+	11
	78	+	12
	79	+	13
	80	+	14
	81	+	15
	82	+	16
	83	+	17
	84	+	18
	85	+	19
	86	+	20
	87	+	21
	88	+	22
	89	+	23
	90	+	24
	91	+
40	92		unless specifically excepted, when the existence of these isomers,
41	93		esters, ethers, and salts is possible within the specific chemical
42	94		designation:
43		-
44	95		1. Acetylmethadol;
45		-
46	96		2. Allylprodine;
47		-
48		-	ENR. S. B. NO. 1152 Page 2
49		-
50	97		3. Alphacetylmethadol;
51		-
52	98		4. Alphameprodine;
53		-
54	99		5. Alphamethadol;
55		-
56	100		6. Benzethidine;
57		-
58	101		7. Betacetylmethadol;
59		-
60	102		8. Betameprodine;
61		-
62	103		9. Betamethadol;
63		-
64	104		10. Betaprodine;
65		-
66	105		11. Clonitazene;
67		-
68	106		12. Dextromoramide;
69		-
70	107		13. Dextrorphan (except its methyl ether);
71		-
72	108		14. Diampromide;
73		-
74	109		15. Diethylthiambutene;
75		-
76	110		16. Dimenoxadol;
77		-
78	111		17. Dimepheptanol;
79		-
80	112		18. Dimethylthiambutene;
81		-
82	113		19. Dioxaphetyl butyrate;
83		-
84	114		20. Dipipanone;
85		-
86	115		21. Ethylmethylthiambutene;
87	116
	117	+	SB1152 HFLR Page 3
	118	+	BOLD FACE denotes Committee Amendments. 1
	119	+	2
	120	+	3
	121	+	4
	122	+	5
	123	+	6
	124	+	7
	125	+	8
	126	+	9
	127	+	10
	128	+	11
	129	+	12
	130	+	13
	131	+	14
	132	+	15
	133	+	16
	134	+	17
	135	+	18
	136	+	19
	137	+	20
	138	+	21
	139	+	22
	140	+	23
	141	+	24
	142	+
88	143		22. Etonitazene;
89		-
90	144		23. Etoxeridine;
91		-
92		-	ENR. S. B. NO. 1152 Page 3
93		-
94	145		24. Furethidine;
95		-
96	146		25. Hydroxypethidine;
97		-
98	147		26. Ketobemidone;
99		-
100	148		27. Levomoramide;
101		-
102	149		28. Levophenacylmorphan;
103		-
104	150		29. Metonitazene;
105		-
106	151		29. 30. Morpheridine;
107		-
108	152		30. 31. Noracymethadol;
109		-
110	153		31. 32. Norlevorphanol;
111		-
112	154		32. 33. Normethadone;
113		-
114	155		33. 34. Norpipanone;
115		-
116	156		34. 35. Phenadoxone;
117		-
118	157		35. 36. Phenampromide;
119		-
120	158		36. 37. Phenomorphan;
121		-
122	159		37. 38. Phenoperidine;
123		-
124	160		38. 39. Piritramide;
125		-
126	161		39. 40. Proheptazine;
127		-
128	162		40. 41. Properidine;
129		-
130	163		41. 42. Racemoramide; or
131		-
132	164		42. 43. Trimeperidine.
133		-
134		-
135		-	ENR. S. B. NO. 1152 Page 4
136	165		B. Any of the following opium derivatives, their salts,
137	166		isomers, and salts of isomers, unless specifically excepte d, when
	167	+
	168	+	SB1152 HFLR Page 4
	169	+	BOLD FACE denotes Committee Amendments. 1
	170	+	2
	171	+	3
	172	+	4
	173	+	5
	174	+	6
	175	+	7
	176	+	8
	177	+	9
	178	+	10
	179	+	11
	180	+	12
	181	+	13
	182	+	14
	183	+	15
	184	+	16
	185	+	17
	186	+	18
	187	+	19
	188	+	20
	189	+	21
	190	+	22
	191	+	23
	192	+	24
	193	+
138	194		the existence of these salts, isomers, and salts of isomers is
139	195		possible within the specific chemical designation:
	196	+	1. Acetorphine;
	197	+	2. Acetyldihydrocodeine;
	198	+	3. Benzylmorphine;
	199	+	4. Codeine methylbromide;
	200	+	5. Codeine-N-Oxide;
	201	+	6. Cyprenorphine;
	202	+	7. Desomorphine;
	203	+	8. Dihydromorphine;
	204	+	9. Etorphine;
	205	+	10. Heroin;
	206	+	11. Hydromorphinol;
	207	+	12. Methyldesorphine;
	208	+	13. Methylhydromorphine;
	209	+	14. Morphine methylbromide;
	210	+	15. Morphine methylsulfonate;
	211	+	16. Morphine-N-Oxide;
	212	+	17. Myrophine;
	213	+	18. Nicocodeine;
	214	+	19. Nicomorphine;
	215	+	20. Normorphine;
	216	+	21. Phoclodine;
	217	+	22. Thebacon;
140	218
141		-	1. Acetorphine;
142		-
143		-	2. Acetyldihydrocodeine;
144		-
145		-	3. Benzylmorphine;
146		-
147		-	4. Codeine methylbromide;
148		-
149		-	5. Codeine-N-Oxide;
150		-
151		-	6. Cyprenorphine;
152		-
153		-	7. Desomorphine;
154		-
155		-	8. Dihydromorphine;
156		-
157		-	9. Etorphine;
158		-
159		-	10. Heroin;
160		-
161		-	11. Hydromorphinol;
162		-
163		-	12. Methyldesorphine;
164		-
165		-	13. Methylhydromorphine;
166		-
167		-	14. Morphine methylbromide;
168		-
169		-	15. Morphine methylsulfonate;
170		-
171		-	16. Morphine-N-Oxide;
172		-
173		-	17. Myrophine;
174		-
175		-	18. Nicocodeine;
176		-
177		-	19. Nicomorphine;
178		-
179		-	ENR. S. B. NO. 1152 Page 5
180		-
181		-	20. Normorphine;
182		-
183		-	21. Phoclodine;
184		-
185		-	22. Thebacon;
	219	+	SB1152 HFLR Page 5
	220	+	BOLD FACE denotes Committee Amendments. 1
	221	+	2
	222	+	3
	223	+	4
	224	+	5
	225	+	6
	226	+	7
	227	+	8
	228	+	9
	229	+	10
	230	+	11
	231	+	12
	232	+	13
	233	+	14
	234	+	15
	235	+	16
	236	+	17
	237	+	18
	238	+	19
	239	+	20
	240	+	21
	241	+	22
	242	+	23
	243	+	24
186	244
187	245		23. N-phenyl-N-[1-(2-phenylethyl)-4-piperidinyl]-acetamide
188	246		(Acetyl fentanyl);
189		-
190	247		24. N-phenyl-N-[1-(2-phenylethyl)-4-piperidinyl]-butenamide
191	248		(Crotonyl fentanyl);
192		-
193	249		25. N-phenyl-N-[1-(2-phenylethyl)-4-piperidinyl]-2-
194	250		furancarboxamide (Furanyl fentanyl);
195		-
196	251		26. N-phenyl-1-(2-phenylethyl)-4-piperidinamine (4-ANPP);
197		-
198	252		27. N-(1-phenethylpiperidin-4-yl)-N-
199	253		phenylcyclopropanecarboxamide (Cyclopropyl fentanyl); or
200		-
201	254		28. N-phenyl-N-[1-(2-phenylethyl)-4-piperidinyl]-butanamide
202	255		(Butyrl fentanyl).
203		-
204	256		C. Any material, compound, mixture, or preparation wh ich
205	257		contains any quantity of the following hal lucinogenic substances,
206	258		their salts, isomers, and salts of isomers, unless specifically
207	259		excepted, when the existence of th ese salts, isomers, and salts of
208	260		isomers is possible within the specific chemical design ation:
209		-
210	261		1. Methcathinone;
211		-
212	262		2. 3, 4-methylenedioxy amphetamine;
213		-
214	263		3. 3, 4-methylenedioxy methamphetamine;
215		-
216	264		4. 5-methoxy-3, 4-methylenedioxy amphetamine;
217		-
218	265		5. 3, 4, 5-trimethoxy amphetamine;
219		-
220	266		6. Bufotenine;
221		-
222		-
223		-	ENR. S. B. NO. 1152 Page 6
224	267		7. Diethyltryptamine;
225		-
226	268		8. Dimethyltryptamine;
227	269
	270	+	SB1152 HFLR Page 6
	271	+	BOLD FACE denotes Committee Amendments. 1
	272	+	2
	273	+	3
	274	+	4
	275	+	5
	276	+	6
	277	+	7
	278	+	8
	279	+	9
	280	+	10
	281	+	11
	282	+	12
	283	+	13
	284	+	14
	285	+	15
	286	+	16
	287	+	17
	288	+	18
	289	+	19
	290	+	20
	291	+	21
	292	+	22
	293	+	23
	294	+	24
	295	+
228	296		9. 4-methyl-2, 5-dimethoxyamphetamine;
229		-
230	297		10. Ibogaine;
231		-
232	298		11. Lysergic acid diethylamide;
233		-
234	299		12. Marijuana;
235		-
236	300		13. Mescaline;
237		-
238	301		14. N-benzylpiperazine;
239		-
240	302		15. N-ethyl-3-piperidyl benzilate;
241		-
242	303		16. N-methyl-3-piperidyl benzilate;
243		-
244	304		17. Psilocybin;
245		-
246	305		18. Psilocyn;
247		-
248	306		19. 2, 5 dimethoxyamphetamine;
249		-
250	307		20. 4 Bromo-2, 5-dimethoxyamphetamine;
251		-
252	308		21. 4 methoxyamphetamine;
253		-
254	309		22. Cyclohexamine;
255		-
256	310		23. Salvia Divinorum;
257		-
258	311		24. Salvinorin A;
259		-
260	312		25. Thiophene Analog of Phencyclidine. Also known as: 1-(1-(2-
261	313		thienyl) cyclohexyl) piperidine; 2 -Thienyl Analog of Phencyclidine;
262	314		TPCP, TCP;
263		-
264	315		26. Phencyclidine (PCP);
265		-
266		-
267		-	ENR. S. B. NO. 1152 Page 7
268	316		27. Pyrrolidine Analog for Phencyclidine . Also known as 1-(1-
269	317		Phenylcyclohexyl) - Pyrrolidine, PCPy, PHP;
270		-
271	318		28. 1-(3-trifluoromethylphenyl) piperazine;
272		-
273	319		29. Flunitrazepam;
274	320
	321	+	SB1152 HFLR Page 7
	322	+	BOLD FACE denotes Committee Amendments. 1
	323	+	2
	324	+	3
	325	+	4
	326	+	5
	327	+	6
	328	+	7
	329	+	8
	330	+	9
	331	+	10
	332	+	11
	333	+	12
	334	+	13
	335	+	14
	336	+	15
	337	+	16
	338	+	17
	339	+	18
	340	+	19
	341	+	20
	342	+	21
	343	+	22
	344	+	23
	345	+	24
	346	+
275	347		30. B-hydroxy-amphetamine;
276		-
277	348		31. B-ketoamphetamine;
278		-
279	349		32. 2,5-dimethoxy-4-nitroamphetamine;
280		-
281	350		33. 2,5-dimethoxy-4-bromophenethylamine;
282		-
283	351		34. 2,5-dimethoxy-4-chlorophenethylamine;
284		-
285	352		35. 2,5-dimethoxy-4-iodoamphetamine;
286		-
287	353		36. 2,5-dimethoxy-4-iodophenethylamine;
288		-
289	354		37. 2,5-dimethoxy-4-methylphenethylamine;
290		-
291	355		38. 2,5-dimethoxy-4-ethylphenethylamine;
292		-
293	356		39. 2,5-dimethoxy-4-fluorophenethylamine;
294		-
295	357		40. 2,5-dimethoxy-4-nitrophenethylamine;
296		-
297	358		41. 2,5-dimethoxy-4-ethylthio-phenethylamine;
298		-
299	359		42. 2,5-dimethoxy-4-isopropylthio-phenethylamine;
300		-
301	360		43. 2,5-dimethoxy-4-propylthio-phenethylamine;
302		-
303	361		44. 2,5-dimethoxy-4-cyclopropylmethylthio -phenethylamine;
304		-
305	362		45. 2,5-dimethoxy-4-tert-butylthio-phenethylamine;
306		-
307	363		46. 2,5-dimethoxy-4-(2-fluoroethylthio)-phenethylamine;
308		-
309	364		47. 5-methoxy-N, N-dimethyltryptamine;
310		-
311		-	ENR. S. B. NO. 1152 Page 8
312		-
313	365		48. N-methyltryptamine;
314		-
315	366		49. A-ethyltryptamine;
316		-
317	367		50. A-methyltryptamine;
318		-
319	368		51. N, N-diethyltryptamine;
320		-
321	369		52. N, N-diisopropyltryptamine;
322		-
323	370		53. N, N-dipropyltryptamine;
324	371
	372	+	SB1152 HFLR Page 8
	373	+	BOLD FACE denotes Committee Amendments. 1
	374	+	2
	375	+	3
	376	+	4
	377	+	5
	378	+	6
	379	+	7
	380	+	8
	381	+	9
	382	+	10
	383	+	11
	384	+	12
	385	+	13
	386	+	14
	387	+	15
	388	+	16
	389	+	17
	390	+	18
	391	+	19
	392	+	20
	393	+	21
	394	+	22
	395	+	23
	396	+	24
	397	+
325	398		54. 5-methoxy-a-methyltryptamine;
326		-
327	399		55. 4-hydroxy-N, N-diethyltryptamine;
328		-
329	400		56. 4-hydroxy-N, N-diisopropyltryptamine;
330		-
331	401		57. 5-methoxy-N, N-diisopropyltryptamine;
332		-
333	402		58. 4-hydroxy-N-isopropyl-N-methyltryptamine;
334		-
335	403		59. 3,4-Methylenedioxymethcathinone (Methylone);
336		-
337	404		60. 3,4-Methylenedioxypyrovalerone (MDPV);
338		-
339	405		61. 4-Methylmethcathinone (Mephedrone);
340		-
341	406		62. 4-methoxymethcathinone;
342		-
343	407		63. 4-Fluoromethcathinone;
344		-
345	408		64. 3-Fluoromethcathinone;
346		-
347	409		65. 1-(8-bromobenzo 1,2-b;4,5-b’ difuran-4-yl)-2-aminopropane;
348		-
349	410		66. 2,5-Dimethoxy-4-chloroamphetamine;
350		-
351	411		67. 4-Methylethcathinone;
352		-
353	412		68. Pyrovalerone;
354		-
355		-	ENR. S. B. NO. 1152 Page 9
356		-
357	413		69. N,N-diallyl-5-methoxytryptamine;
358		-
359	414		70. 3,4-Methylenedioxy-N-ethylcathinone (Ethylone);
360		-
361	415		71. B-keto-N-Methylbenzodioxolylbutanamine (Butylon e);
362		-
363	416		72. B-keto-Methylbenzodioxolylpentanamine (Pentylone);
364		-
365	417		73. Alpha-Pyrrolidinopentiophenone;
366		-
367	418		74. 4-Fluoroamphetamine;
368		-
369	419		75. Pentedrone;
370		-
371	420		76. 4’-Methyl-a-pyrrolidinohexaphenone;
372		-
373	421		77. 2,5-dimethoxy-4-(n)-propylphenethylamine;
374	422
	423	+	SB1152 HFLR Page 9
	424	+	BOLD FACE denotes Committee Amendments. 1
	425	+	2
	426	+	3
	427	+	4
	428	+	5
	429	+	6
	430	+	7
	431	+	8
	432	+	9
	433	+	10
	434	+	11
	435	+	12
	436	+	13
	437	+	14
	438	+	15
	439	+	16
	440	+	17
	441	+	18
	442	+	19
	443	+	20
	444	+	21
	445	+	22
	446	+	23
	447	+	24
	448	+
375	449		78. 2,5-dimethoxyphenethylamine;
376		-
377	450		79. 1,4-Dibenzylpiperazine;
378		-
379	451		80. N,N-Dimethylamphetamine;
380		-
381	452		81. 4-Fluoromethamphetamine;
382		-
383	453		82. 4-Chloro-2,5-dimethoxy-N-(2-methoxybenzyl)pheneth ylamine
384	454		(25C-NBOMe);
385		-
386	455		83. 4-Iodo-2,5-dimethoxy-N-(2-methoxybenzyl)phenethylamine
387	456		(25I-NBOMe);
388		-
389	457		84. 4-Bromo-2,5-dimethoxy-N-(2-methoxybenzy)phenethylamine
390	458		(25B-NBOMe);
391		-
392	459		85. 1-(4-Fluorophenyl)piperazine;
393		-
394	460		86. Methoxetamine;
395		-
396	461		87. 3,4-dichloro-N[2-dimethylamino)cyclohexyl]-N-
397	462		methylbenzamide;
398		-
399		-	ENR. S. B. NO. 1152 Page 10
400		-
401	463		88. N-ethyl hexadrone;
402		-
403	464		89. Isopropyl-U-47700;
404		-
405	465		90. Para-fluorobutyrl fentanyl;
406		-
407	466		91. Fluoro isobutryrl fentanyl;
408		-
409	467		92. 3-Hydroxy Phencyclidine (PCP); or
410		-
411	468		93. 3-methoxy Phencyclidine (PCP) ;
412		-
413	469		94. Flualprazolam; or
414		-
415	470		95. Flubromazolam.
416		-
417	471		D. Unless specifically excepted or unless listed in a di fferent
418	472		schedule, any material, compound, mixture, or prepara tion which
	473	+
	474	+	SB1152 HFLR Page 10
	475	+	BOLD FACE denotes Committee Amendments. 1
	476	+	2
	477	+	3
	478	+	4
	479	+	5
	480	+	6
	481	+	7
	482	+	8
	483	+	9
	484	+	10
	485	+	11
	486	+	12
	487	+	13
	488	+	14
	489	+	15
	490	+	16
	491	+	17
	492	+	18
	493	+	19
	494	+	20
	495	+	21
	496	+	22
	497	+	23
	498	+	24
	499	+
419	500		contains any quantity of the f ollowing substances having stimulant
420	501		or depressant effect on the central nervous system:
421		-
422	502		1. Fenethylline;
423		-
424	503		2. Mecloqualone;
425		-
426	504		3. N-ethylamphetamine;
427		-
428	505		4. Methaqualone;
429		-
430	506		5. Gamma-Hydroxybutyric Acid, also known a s GHB, gamma-
431	507		hydroxybutyrate, 4-hydroxybutyrate, 4-hydroxybutanoic acid, sodium
432	508		oxybate, and sodium oxybutyrate;
433		-
434	509		6. Gamma-Butyrolactone (GBL) as packaged, marketed,
435	510		manufactured or promoted for human consumption, with the exception
436	511		of legitimate food add itive and manufacturing purposes;
437		-
438	512		7. Gamma Hydroxyvalerate (GHV) as packaged, marketed, or
439	513		manufactured for human consumption, with th e exception of legitimate
440	514		food additive and manufacturing purposes ;
441		-
442		-
443		-	ENR. S. B. NO. 1152 Page 11
444	515		8. Gamma Valerolactone (GVL) as packaged, marketed , or
445	516		manufactured for human consumption, with the exception of legitimate
446	517		food additive and manufacturing purposes;
447		-
448	518		9. 1,4 Butanediol (1,4 BD or BDO) as packaged, marketed,
449	519		manufactured, or promoted for human consumption with the exception
450	520		of legitimate manufacturing purposes; or
451		-
452	521		10. N-ethylpentylone.
453		-
454	522		E. 1. The following industrial uses of Gamma -Butyrolactone,
455	523		Gamma Hydroxyvalerate, Gam ma Valerolactone, or 1,4 Butanediol are
	524	+
	525	+	SB1152 HFLR Page 11
	526	+	BOLD FACE denotes Committee Amendments. 1
	527	+	2
	528	+	3
	529	+	4
	530	+	5
	531	+	6
	532	+	7
	533	+	8
	534	+	9
	535	+	10
	536	+	11
	537	+	12
	538	+	13
	539	+	14
	540	+	15
	541	+	16
	542	+	17
	543	+	18
	544	+	19
	545	+	20
	546	+	21
	547	+	22
	548	+	23
	549	+	24
	550	+
456	551		excluded from all schedule s of controlled substan ces under this
457	552		title:
458		-
459	553		a. pesticides,
460		-
461	554		b. photochemical etching,
462		-
463	555		c. electrolytes of small batteries or capacitors,
464		-
465	556		d. viscosity modifiers in polyurethane,
466		-
467	557		e. surface etching of metal coated plastics,
468		-
469	558		f. organic paint disbursements for water soluble inks,
470		-
471	559		g. pH regulators in the dyeing of wool and polyamide
472	560		fibers,
473		-
474	561		h. foundry chemistry as a catalyst during curing,
475		-
476	562		i. curing agents in many coating systems based on
477	563		urethanes and amides,
478		-
479	564		j. additives and flavoring agents in food, confection ary,
480	565		and beverage products,
481		-
482	566		k. synthetic fiber and clothing production,
483		-
484	567		l. tetrahydrofuran production,
485		-
486		-
487		-	ENR. S. B. NO. 1152 Page 12
488	568		m. gamma butyrolactone production,
489		-
490	569		n. polybutylene terephthalate resin production,
491		-
492	570		o. polyester raw materials for polyurethane elastomers
493	571		and foams,
494		-
495	572		p. coating resin raw materi al, and
496		-
497	573		q. as an intermediate in the manufacture of other
498	574		chemicals and pharmac euticals.
	575	+
	576	+	SB1152 HFLR Page 12
	577	+	BOLD FACE denotes Committee Amendments. 1
	578	+	2
	579	+	3
	580	+	4
	581	+	5
	582	+	6
	583	+	7
	584	+	8
	585	+	9
	586	+	10
	587	+	11
	588	+	12
	589	+	13
	590	+	14
	591	+	15
	592	+	16
	593	+	17
	594	+	18
	595	+	19
	596	+	20
	597	+	21
	598	+	22
	599	+	23
	600	+	24
499	601
500	602		2. At the request of any person, the Director may exempt any
501	603		other product containing Gamma-Butyrolactone, Gamma Hydroxyvalerate,
502	604		Gamma Valerolactone, or 1,4 Butanedi ol from being included as a
503	605		Schedule I controlled substance if such product is labeled,
504	606		marketed, manufactured and distributed for legitimate industrial use
505	607		in a manner that reduces or eliminates the likelihood of abuse.
506		-
507	608		3. In making a determination regar ding an industrial product,
508	609		the Director, after notice and hearing, shall consi der the
509	610		following:
510		-
511	611		a. the history and current pattern of abuse,
512		-
513	612		b. the name and labeling of the product,
514		-
515	613		c. the intended manner of distribution, advertisi ng and
516	614		promotion of the product, and
517		-
518	615		d. other factors as may be relevant to and consistent
519	616		with the public health and safety.
520		-
521	617		4. The hearing shall be held in accordance with the procedures
522	618		of the Administrative Procedures Act.
523		-
524	619		F. Any material, compound, mixture, or preparation , whether
525	620		produced directly or indirectly from a substance of vegetable origin
526	621		or independently by means of chemical synthesis, or by a combination
527	622		of extraction and chemical synthesis, that contains any quantity of
528	623		the following substances, or that contai ns any of their salts,
529	624		isomers, and salts of isomers when the existence of thes e salts,
530	625
531		-	ENR. S. B. NO. 1152 Page 13
	626	+	SB1152 HFLR Page 13
	627	+	BOLD FACE denotes Committee Amendments. 1
	628	+	2
	629	+	3
	630	+	4
	631	+	5
	632	+	6
	633	+	7
	634	+	8
	635	+	9
	636	+	10
	637	+	11
	638	+	12
	639	+	13
	640	+	14
	641	+	15
	642	+	16
	643	+	17
	644	+	18
	645	+	19
	646	+	20
	647	+	21
	648	+	22
	649	+	23
	650	+	24
	651	+
532	652		isomers, and salts of isomers is possible within the specific
533	653		chemical designation:
534		-
535	654		1. JWH-004;
536		-
537	655		2. JWH-007;
538		-
539	656		3. JWH-009;
540		-
541	657		4. JWH-015;
542		-
543	658		5. JWH-016;
544		-
545	659		6. JWH-018;
546		-
547	660		7. JWH-019;
548		-
549	661		8. JWH-020;
550		-
551	662		9. JWH-030;
552		-
553	663		10. JWH-046;
554		-
555	664		11. JWH-047;
556		-
557	665		12. JWH-048;
558		-
559	666		13. JWH-049;
560		-
561	667		14. JWH-050;
562		-
563	668		15. JWH-070;
564		-
565	669		16. JWH-071;
566		-
567	670		17. JWH-072;
568		-
569	671		18. JWH-073;
570		-
571	672		19. JWH-076;
572		-
573	673		20. JWH-079;
574		-
575		-	ENR. S. B. NO. 1152 Page 14
576		-
577	674		21. JWH-080;
578		-
579	675		22. JWH-081;
580	676
	677	+	SB1152 HFLR Page 14
	678	+	BOLD FACE denotes Committee Amendments. 1
	679	+	2
	680	+	3
	681	+	4
	682	+	5
	683	+	6
	684	+	7
	685	+	8
	686	+	9
	687	+	10
	688	+	11
	689	+	12
	690	+	13
	691	+	14
	692	+	15
	693	+	16
	694	+	17
	695	+	18
	696	+	19
	697	+	20
	698	+	21
	699	+	22
	700	+	23
	701	+	24
	702	+
581	703		23. JWH-082;
582		-
583	704		24. JWH-094;
584		-
585	705		25. JWH-096;
586		-
587	706		26. JWH-098;
588		-
589	707		27. JWH-116;
590		-
591	708		28. JWH-120;
592		-
593	709		29. JWH-122;
594		-
595	710		30. JWH-145;
596		-
597	711		31. JWH-146;
598		-
599	712		32. JWH-147;
600		-
601	713		33. JWH-148;
602		-
603	714		34. JWH-149;
604		-
605	715		35. JWH-150;
606		-
607	716		36. JWH-156;
608		-
609	717		37. JWH-167;
610		-
611	718		38. JWH-175;
612		-
613	719		39. JWH-180;
614		-
615	720		40. JWH-181;
616		-
617	721		41. JWH-182;
618		-
619		-	ENR. S. B. NO. 1152 Page 15
620		-
621	722		42. JWH-184;
622		-
623	723		43. JWH-185;
624		-
625	724		44. JWH-189;
626		-
627	725		45. JWH-192;
628		-
629	726		46. JWH-193;
630	727
	728	+	SB1152 HFLR Page 15
	729	+	BOLD FACE denotes Committee Amendments. 1
	730	+	2
	731	+	3
	732	+	4
	733	+	5
	734	+	6
	735	+	7
	736	+	8
	737	+	9
	738	+	10
	739	+	11
	740	+	12
	741	+	13
	742	+	14
	743	+	15
	744	+	16
	745	+	17
	746	+	18
	747	+	19
	748	+	20
	749	+	21
	750	+	22
	751	+	23
	752	+	24
	753	+
631	754		47. JWH-194;
632		-
633	755		48. JWH-195;
634		-
635	756		49. JWH-196;
636		-
637	757		50. JWH-197;
638		-
639	758		51. JWH-198;
640		-
641	759		52. JWH-199;
642		-
643	760		53. JWH-200;
644		-
645	761		54. JWH-201;
646		-
647	762		55. JWH-202;
648		-
649	763		56. JWH-203;
650		-
651	764		57. JWH-204;
652		-
653	765		58. JWH-205;
654		-
655	766		59. JWH-206;
656		-
657	767		60. JWH-207;
658		-
659	768		61. JWH-208;
660		-
661	769		62. JWH-209;
662		-
663		-	ENR. S. B. NO. 1152 Page 16
664		-
665	770		63. JWH-210;
666		-
667	771		64. JWH-211;
668		-
669	772		65. JWH-212;
670		-
671	773		66. JWH-213;
672		-
673	774		67. JWH-234;
674		-
675	775		68. JWH-235;
676		-
677	776		69. JWH-236;
678		-
679	777		70. JWH-237;
680	778
	779	+	SB1152 HFLR Page 16
	780	+	BOLD FACE denotes Committee Amendments. 1
	781	+	2
	782	+	3
	783	+	4
	784	+	5
	785	+	6
	786	+	7
	787	+	8
	788	+	9
	789	+	10
	790	+	11
	791	+	12
	792	+	13
	793	+	14
	794	+	15
	795	+	16
	796	+	17
	797	+	18
	798	+	19
	799	+	20
	800	+	21
	801	+	22
	802	+	23
	803	+	24
	804	+
681	805		71. JWH-239;
682		-
683	806		72. JWH-240;
684		-
685	807		73. JWH-241;
686		-
687	808		74. JWH-242;
688		-
689	809		75. JWH-243;
690		-
691	810		76. JWH-244;
692		-
693	811		77. JWH-245;
694		-
695	812		78. JWH-246;
696		-
697	813		79. JWH-248;
698		-
699	814		80. JWH-249;
700		-
701	815		81. JWH-250;
702		-
703	816		82. JWH-251;
704		-
705	817		83. JWH-252;
706		-
707		-	ENR. S. B. NO. 1152 Page 17
708		-
709	818		84. JWH-253;
710		-
711	819		85. JWH-262;
712		-
713	820		86. JWH-292;
714		-
715	821		87. JWH-293;
716		-
717	822		88. JWH-302;
718		-
719	823		89. JWH-303;
720		-
721	824		90. JWH-304;
722		-
723	825		91. JWH-305;
724		-
725	826		92. JWH-306;
726		-
727	827		93. JWH-307;
728		-
729	828		94. JWH-308;
730	829
	830	+	SB1152 HFLR Page 17
	831	+	BOLD FACE denotes Committee Amendments. 1
	832	+	2
	833	+	3
	834	+	4
	835	+	5
	836	+	6
	837	+	7
	838	+	8
	839	+	9
	840	+	10
	841	+	11
	842	+	12
	843	+	13
	844	+	14
	845	+	15
	846	+	16
	847	+	17
	848	+	18
	849	+	19
	850	+	20
	851	+	21
	852	+	22
	853	+	23
	854	+	24
	855	+
731	856		95. JWH-311;
732		-
733	857		96. JWH-312;
734		-
735	858		97. JWH-313;
736		-
737	859		98. JWH-314;
738		-
739	860		99. JWH-315;
740		-
741	861		100. JWH-316;
742		-
743	862		101. JWH-346;
744		-
745	863		102. JWH-348;
746		-
747	864		103. JWH-363;
748		-
749	865		104. JWH-364;
750		-
751		-	ENR. S. B. NO. 1152 Page 18
752		-
753	866		105. JWH-365;
754		-
755	867		106. JWH-367;
756		-
757	868		107. JWH-368;
758		-
759	869		108. JWH-369;
760		-
761	870		109. JWH-370;
762		-
763	871		110. JWH-371;
764		-
765	872		111. JWH-373;
766		-
767	873		112. JWH-386;
768		-
769	874		113. JWH-387;
770		-
771	875		114. JWH-392;
772		-
773	876		115. JWH-394;
774		-
775	877		116. JWH-395;
776		-
777	878		117. JWH-397;
778		-
779	879		118. JWH-398;
780	880
	881	+	SB1152 HFLR Page 18
	882	+	BOLD FACE denotes Committee Amendments. 1
	883	+	2
	884	+	3
	885	+	4
	886	+	5
	887	+	6
	888	+	7
	889	+	8
	890	+	9
	891	+	10
	892	+	11
	893	+	12
	894	+	13
	895	+	14
	896	+	15
	897	+	16
	898	+	17
	899	+	18
	900	+	19
	901	+	20
	902	+	21
	903	+	22
	904	+	23
	905	+	24
	906	+
781	907		119. JWH-399;
782		-
783	908		120. JWH-400;
784		-
785	909		121. JWH-412;
786		-
787	910		122. JWH-413;
788		-
789	911		123. JWH-414;
790		-
791	912		124. JWH-415;
792		-
793	913		125. CP-55, 940;
794		-
795		-	ENR. S. B. NO. 1152 Page 19
796		-
797	914		126. CP-47, 497;
798		-
799	915		127. HU-210;
800		-
801	916		128. HU-211;
802		-
803	917		129. WIN-55, 212-2;
804		-
805	918		130. AM-2201;
806		-
807	919		131. AM-2233;
808		-
809	920		132. JWH-018 adamantyl-carboxamide;
810		-
811	921		133. AKB48;
812		-
813	922		134. JWH-122 N-(4-pentenyl)analog;
814		-
815	923		135. MAM2201;
816		-
817	924		136. URB597;
818		-
819	925		137. URB602;
820		-
821	926		138. URB754;
822		-
823	927		139. UR144;
824		-
825	928		140. XLR11;
826		-
827	929		141. A-796,260;
828		-
829	930		142. STS-135;
830	931
	932	+	SB1152 HFLR Page 19
	933	+	BOLD FACE denotes Committee Amendments. 1
	934	+	2
	935	+	3
	936	+	4
	937	+	5
	938	+	6
	939	+	7
	940	+	8
	941	+	9
	942	+	10
	943	+	11
	944	+	12
	945	+	13
	946	+	14
	947	+	15
	948	+	16
	949	+	17
	950	+	18
	951	+	19
	952	+	20
	953	+	21
	954	+	22
	955	+	23
	956	+	24
	957	+
831	958		143. AB-FUBINACA;
832		-
833	959		144. AB-PINACA;
834		-
835	960		145. PB-22;
836		-
837	961		146. AKB48 N-5-Fluorpentyl;
838		-
839		-	ENR. S. B. NO. 1152 Page 20
840		-
841	962		147. AM1248;
842		-
843	963		148. FUB-PB-22;
844		-
845	964		149. ADB-FUBINACA;
846		-
847	965		150. BB-22;
848		-
849	966		151. 5-Fluoro PB-22; or
850		-
851	967		152. 5-Fluoro AKB-48.
852		-
853	968		G. In addition to those substances liste d in subsection F of
854	969		this section, unless specifically excepted or unless listed in
855	970		another schedule, any material, compound, mixture, or preparation
856	971		which contains any quantity of a synthetic cannabinoid found to be
857	972		in any of the following chemical groups :
858		-
859	973		1. Naphthoylindoles: any compound containing a 3 -(1-
860	974		naphthoyl)indole structure with or without substitution at the
861	975		nitrogen atom of the indole ring by an alkyl, halo alkyl, cyanoalkyl,
862	976		alkenyl, cycloalkylmethyl, cycloalkylethyl, benzyl, halobenzyl, 1 -
863	977		(N-methyl-2-piperidinyl)methyl, 2-(4-morpholinyl)ethyl, 1 -(N-methyl-
864	978		2-pyrrolidinyl)methyl, 1 -(N-methyl-3- morpholinyl)methyl,
865	979		(tetrahydropyran-4-yl)methyl, 1-methylazepanyl, phenyl, or
866	980		halophenyl group, whether or not further substituted on the indole
867	981		ring to any extent, and whether or not substituted on the naphthyl
	982	+
	983	+	SB1152 HFLR Page 20
	984	+	BOLD FACE denotes Committee Amendments. 1
	985	+	2
	986	+	3
	987	+	4
	988	+	5
	989	+	6
	990	+	7
	991	+	8
	992	+	9
	993	+	10
	994	+	11
	995	+	12
	996	+	13
	997	+	14
	998	+	15
	999	+	16
	1000	+	17
	1001	+	18
	1002	+	19
	1003	+	20
	1004	+	21
	1005	+	22
	1006	+	23
	1007	+	24
	1008	+
868	1009		ring to any extent. Naphthoylindoles include, but are not limited
869	1010		to:
870		-
871	1011		a. 1-[2-(4-morpholinyl)ethyl]-3-(1-naphthoyl)indole (JWH-
872	1012		200),
873		-
874	1013		b. 1-(5-fluoropentyl)-3-(1-naphthoyl)indole (AM2201),
875		-
876	1014		c. 1-pentyl-3-(1-naphthoyl)indole (JWH-018),
877		-
878	1015		d. 1-butyl-3-(1-naphthoyl)indole (JWH-073),
879		-
880	1016		e. 1-pentyl-3-(4-methoxy-1-naphthoyl)indole (JWH -081),
881		-
882		-
883		-	ENR. S. B. NO. 1152 Page 21
884	1017		f. 1-propyl-2-methyl-3-(1-naphthoyl)indole (JWH-015),
885		-
886	1018		g. 1-hexyl-3-(1-naphthoyl)indole (JWH -019),
887		-
888	1019		h. 1-pentyl-3-(4-methyl-1-naphthoyl)indole (JWH-122),
889		-
890	1020		i. 1-pentyl-3-(4-ethyl-1-naphthoyl)indole (JWH-210),
891		-
892	1021		j. 1-pentyl-3-(4-chloro-1-naphthoyl)indole (JWH -398),
893		-
894	1022		k. 1-pentyl-2-methyl-3-(1-naphthoyl)indole (JWH-007),
895		-
896	1023		l. 1-pentyl-3-(7-methoxy-1-naphthoyl)indole (JWH -164),
897		-
898	1024		m. 1-pentyl-2-methyl-3-(4-methoxy-1-naphthoyl)indole
899	1025		(JWH-098),
900		-
901	1026		n. 1-pentyl-3-(4-fluoro-1-naphthoyl)indole (JWH-412),
902		-
903	1027		o. 1-[1-(N-methyl-2-piperidinyl)methyl]-3-(1-
904	1028		naphthoyl)indole (AM-1220),
905		-
906	1029		p. 1-(5-fluoropentyl)-3-(4-methyl-1-naphthoyl)indole
907	1030		(MAM-2201), or
	1031	+	q. 1-(4-cyanobutyl)-3-(1-naphthoyl)indole (AM -2232);
908	1032
909		-	q. 1-(4-cyanobutyl)-3-(1-naphthoyl)indole (AM -2232);
	1033	+	SB1152 HFLR Page 21
	1034	+	BOLD FACE denotes Committee Amendments. 1
	1035	+	2
	1036	+	3
	1037	+	4
	1038	+	5
	1039	+	6
	1040	+	7
	1041	+	8
	1042	+	9
	1043	+	10
	1044	+	11
	1045	+	12
	1046	+	13
	1047	+	14
	1048	+	15
	1049	+	16
	1050	+	17
	1051	+	18
	1052	+	19
	1053	+	20
	1054	+	21
	1055	+	22
	1056	+	23
	1057	+	24
910	1058
911	1059		2. Naphthylmethylindoles: any compound c ontaining a 1H-indol-3-
912	1060		yl-(1-naphthyl)methane structure with or without substit ution at the
913	1061		nitrogen atom of the indole ring by an alkyl, haloalkyl, cyanoalkyl,
914	1062		alkenyl, cycloalkylmethyl, cycloalkylethyl, benzyl, halobenzyl, 1 -
915	1063		(N-methyl-2-piperidinyl)methyl, 2-(4-morpholinyl)ethyl, 1 -(N-methyl-
916	1064		2-pyrrolidinyl)methyl, 1 -(N-methyl-3- morpholinyl)methyl,
917	1065		(tetrahydropyran-4-yl)methyl, 1-methylazepanyl, phenyl, or
918	1066		halophenyl group, whether or not further substituted on the indole
919	1067		ring to any extent, and whether o r not substituted on the naphthyl
920	1068		ring to any extent. Naphthylmethylindoles in clude, but are not
921	1069		limited to, (1-pentylindol-3-yl)(1-naphthyl)methane (JWH -175);
922		-
923	1070		3. Naphthoylpyrroles: any compound containing a 3 -(1-
924	1071		naphthoyl)pyrrole structure with or witho ut substitution at the
925	1072		nitrogen atom of the pyrrole ring by an alkyl, haloalkyl ,
926		-
927		-	ENR. S. B. NO. 1152 Page 22
928	1073		cyanoalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, benzyl,
929	1074		halobenzyl, 1-(N-methyl-2-piperidinyl)methyl, 2-(4-
930	1075		morpholinyl)ethyl, 1 -(N-methyl-2-pyrrolidinyl)methyl, 1-(N-methyl-3-
931	1076		morpholinyl)methyl, (tetrahydropyran -4-yl)methyl, 1-methylazepanyl,
932	1077		phenyl, or halophenyl group, whether or not further substituted on
933	1078		the pyrrole ring to any extent, and whether or not substituted on
934	1079		the naphthyl group to an y extent. Naphthoylpyrroles include, but
935	1080		are not limited to:
	1081	+	a. 1-hexyl-2-phenyl-4-(1-naphthoyl)pyrrole (JWH-147),
936	1082
937		-	a. 1-hexyl-2-phenyl-4-(1-naphthoyl)pyrrole (J WH-147),
	1083	+	SB1152 HFLR Page 22
	1084	+	BOLD FACE denotes Committee Amendments. 1
	1085	+	2
	1086	+	3
	1087	+	4
	1088	+	5
	1089	+	6
	1090	+	7
	1091	+	8
	1092	+	9
	1093	+	10
	1094	+	11
	1095	+	12
	1096	+	13
	1097	+	14
	1098	+	15
	1099	+	16
	1100	+	17
	1101	+	18
	1102	+	19
	1103	+	20
	1104	+	21
	1105	+	22
	1106	+	23
	1107	+	24
938	1108
939	1109		b. 1-pentyl-5-(2-methylphenyl)-3-(1-naphthoyl)pyrrole
940	1110		(JWH-370),
941		-
942	1111		c. 1-pentyl-3-(1-naphthoyl)pyrrole (JWH-030), or
943		-
944	1112		d. 1-hexyl-5-phenyl-3-(1-naphthoyl)pyrrole (JWH -147);
945		-
946	1113		4. Naphthylideneindenes: any compound containing a 1 -(1-
947	1114		naphthylmethylene)indene structure with or without substitution at
948	1115		the 3-position of the indene ring by a n alkyl, haloalkyl,
949	1116		cyanoalkyl, alkenyl, cycloalkylmethyl, cycloal kylethyl, benzyl,
950	1117		halobenzyl, 1-(N-methyl-2-piperidinyl)methyl, 2 -(4-
951	1118		morpholinyl)ethyl, 1 -(N-methyl-2-pyrrolidinyl)methyl, 1-(N-methyl-3-
952	1119		morpholinyl)methyl, (tetrahydropyran -4-yl)methyl, 1-methylazepanyl,
953	1120		phenyl, or halophenyl group, whether or not further substituted on
954	1121		the indene group to any extent, and whether or not substituted on
955	1122		the naphthyl group t o any extent. Naphthylmethylindenes include,
956	1123		but are not limited to, (1 -[(3-pentyl)-1H-inden-1-
957	1124		ylidene)methyl]naphthalene (JWH -176);
958		-
959	1125		5. Phenylacetylindoles: any compound conta ining a 3-
960	1126		phenylacetylindole structure with or without substitution at the
961	1127		nitrogen atom of the indole ring by alkyl, haloalkyl, cyanoalkyl,
962	1128		alkenyl, cycloalkylmethyl, cycloalkylethyl, benzyl, halobenzyl, 1 -
963	1129		(N-methyl-2-piperidinyl)methyl, 2-(4-morpholinyl)ethyl, 1-(N-methyl-
964	1130		2-pyrrolidinyl)methyl, 1 -(N-methyl-3- morpholinyl)methyl,
965	1131		(tetrahydropyran-4-yl)methyl, 1-methylazepanyl, phenyl, or
966	1132		halophenyl group, whether or no t further substituted on the indole
	1133	+
	1134	+	SB1152 HFLR Page 23
	1135	+	BOLD FACE denotes Committee Amendments. 1
	1136	+	2
	1137	+	3
	1138	+	4
	1139	+	5
	1140	+	6
	1141	+	7
	1142	+	8
	1143	+	9
	1144	+	10
	1145	+	11
	1146	+	12
	1147	+	13
	1148	+	14
	1149	+	15
	1150	+	16
	1151	+	17
	1152	+	18
	1153	+	19
	1154	+	20
	1155	+	21
	1156	+	22
	1157	+	23
	1158	+	24
	1159	+
967	1160		ring to any extent, and whethe r or not substituted on the phenyl
968	1161		ring to any extent. Phenylacetylindoles include, but are not
969	1162		limited to:
970		-
971		-	ENR. S. B. NO. 1152 Page 23
972		-
973	1163		a. 1-pentyl-3-(2-methoxyphenylacetyl)indole (JWH -250),
974		-
975	1164		b. 1-(2-cyclohexylethyl)-3-(2-methoxyphenylacetyl)indole
976	1165		(RCS-8),
977		-
978	1166		c. 1-pentyl-3-(2-chlorophenylacetyl)indole (JWH -203),
979		-
980	1167		d. 1-pentyl-3-(2-methylphenylacetyl)indole (JWH -251),
981		-
982	1168		e. 1-pentyl-3-(4-methoxyphenylacetyl)indole (JWH-201), or
983		-
984	1169		f. 1-pentyl-3-(3-methoxyphenylacetyl)indole (JWH -302);
985		-
986	1170		6. Cyclohexylphenols: any compound containing a 2 -(3-
987	1171		hydroxycyclohexyl)phenol struc ture with or without substitution at
988	1172		the 5-position of the phenolic ring by an alkyl, haloalkyl,
989	1173		cyanoalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, benzyl,
990	1174		halobenzyl, 1-(N-methyl-2-piperidinyl)methyl, 2 -(4-
991	1175		morpholinyl)ethyl, 1 -(N-methyl-2-pyrrolidinyl)methyl, 1-(N-methyl-3-
992	1176		morpholinyl)methyl, (tetrahydropyran -4-yl)methyl, 1-methylazepanyl,
993	1177		phenyl, or halophenyl group, and whether or not further substituted
994	1178		on the cyclohexyl ring to any extent. Cyclohexylphenols include,
995	1179		but are not limited to:
996		-
997	1180		a. 5-(1,1-dimethylheptyl)-2-[(1R,3S)-3-
998	1181		hydroxycyclohexyl]-phenol (CP-47,497),
	1182	+
	1183	+	SB1152 HFLR Page 24
	1184	+	BOLD FACE denotes Committee Amendments. 1
	1185	+	2
	1186	+	3
	1187	+	4
	1188	+	5
	1189	+	6
	1190	+	7
	1191	+	8
	1192	+	9
	1193	+	10
	1194	+	11
	1195	+	12
	1196	+	13
	1197	+	14
	1198	+	15
	1199	+	16
	1200	+	17
	1201	+	18
	1202	+	19
	1203	+	20
	1204	+	21
	1205	+	22
	1206	+	23
	1207	+	24
999	1208
1000	1209		b. 5-(1,1-dimethyloctyl)-2-[(1R,3S)-3-hydroxycyclohexyl]-
1001	1210		phenol (cannabicyclohexanol; CP -47,497 C8 homologue),
1002	1211		or
1003		-
1004	1212		c. 5-(1,1-dimethylheptyl)-2-[(1R,2R)-5-hydroxy-2-(3-
1005	1213		hydroxypropyl)cyclohexyl]-phenol (CP 55, 940);
1006		-
1007	1214		7. Benzoylindoles: any compound conta ining a 3-(benzoyl)indole
1008	1215		structure with or without substitution at the nitrogen atom of the
1009	1216		indole ring by an alkyl, haloalkyl, cyanoalkyl, alkenyl,
1010	1217		cycloalkylmethyl, cycloalkylethyl, ben zyl, halobenzyl, 1-(N-methyl-
1011	1218		2-piperidinyl)methyl, 2 -(4-morpholinyl)ethyl, 1-(N-methyl-2-
1012	1219		pyrrolidinyl)methyl, 1-(N-methyl-3- morpholinyl)methyl,
1013	1220		(tetrahydropyran-4-yl)methyl, 1-methylazepanyl, phenyl, or
1014		-
1015		-	ENR. S. B. NO. 1152 Page 24
1016	1221		halophenyl group, whether or not further substituted on the indole
1017	1222		ring to any extent, and whether or not substituted on the phenyl
1018	1223		group to any extent. Benzoylindoles include, but are not limited
1019	1224		to:
1020		-
1021	1225		a. 1-pentyl-3-(4-methoxybenzoyl)indole (RCS-4),
1022		-
1023	1226		b. 1-[2-(4-morpholinyl)ethyl]-2-methyl-3-(4-
1024	1227		methoxybenzoyl)indole (Pravadoline or WIN 48, 098),
1025		-
1026	1228		c. 1-(5-fluoropentyl)-3-(2-iodobenzoyl)indole (AM-694),
1027		-
1028	1229		d. 1-pentyl-3-(2-iodobenzoyl)indole (AM -679), or
1029		-
1030	1230		e. 1-[1-(N-methyl-2-piperidinyl)methyl]-3-(2-
1031	1231		iodobenzoyl)indole (AM -2233);
	1232	+
	1233	+	SB1152 HFLR Page 25
	1234	+	BOLD FACE denotes Committee Amendments. 1
	1235	+	2
	1236	+	3
	1237	+	4
	1238	+	5
	1239	+	6
	1240	+	7
	1241	+	8
	1242	+	9
	1243	+	10
	1244	+	11
	1245	+	12
	1246	+	13
	1247	+	14
	1248	+	15
	1249	+	16
	1250	+	17
	1251	+	18
	1252	+	19
	1253	+	20
	1254	+	21
	1255	+	22
	1256	+	23
	1257	+	24
1032	1258
1033	1259		8. Cyclopropoylindoles: Any compound containing a 3-
1034	1260		(cyclopropoyl)indole structure with substitutio n at the nitrogen
1035	1261		atom of the indole ring by an alkyl, haloalkyl, cyanoalkyl, alkenyl,
1036	1262		cycloalkylmethyl, cycloalkylethyl, benzyl, halobenzyl, 1 -(N-methyl-
1037	1263		2-piperidinyl)methyl, 2-(4-morpholinyl)ethyl, 1-(N-methyl-2-
1038	1264		pyrrolidinyl)methyl, 1 -(N-methyl-3- morpholinyl)methyl,
1039	1265		(tetrahydropyran-4-yl)methyl, 1-methylazepanyl, phenyl, or
1040	1266		halophenyl group, whether or not further substituted in the indole
1041	1267		ring to any extent and whether or not substituted in t he
1042	1268		cyclopropoyl ring to any extent . Cyclopropoylindoles inclu de, but
1043	1269		are not limited to:
1044		-
1045	1270		a. 1-pentyl-3-(2,2,3,3-tetramethylcyclopropoyl)indole
1046	1271		(UR-144),
1047		-
1048	1272		b. 1-(5-chloropentyl)-3-(2,2,3,3-
1049	1273		tetramethylcyclopropoyl)indole (5Cl -UR-144), or
1050		-
1051	1274		c. 1-(5-fluoropentyl)-3-(2,2,3,3-
1052	1275		tetramethylcyclopropoyl)indole (XLR11);
1053		-
1054	1276		9. Indole Amides: Any compound containing a 1H-Indole-3-
1055	1277		carboxamide structure with or without substitution at the nitrogen
1056	1278		atom of the indole ring by an alkyl, haloalkyl, cyanoalk yl, alkenyl,
1057	1279		cycloalkylmethyl, cycloalkylethyl, benzyl, halobenzyl, 1 -(N-methyl-
1058		-
1059		-	ENR. S. B. NO. 1152 Page 25
1060	1280		2-piperidinyl)methyl, 2-(4-morpholinyl)ethyl, 1-(N-methyl-2-
1061	1281		pyrrolidinyl)methyl, 1 -(N-methyl-3- morpholinyl)methyl,
1062	1282		(tetrahydropyran-4-yl)methyl, 1-methylazepanyl, phenyl, or
	1283	+
	1284	+	SB1152 HFLR Page 26
	1285	+	BOLD FACE denotes Committee Amendments. 1
	1286	+	2
	1287	+	3
	1288	+	4
	1289	+	5
	1290	+	6
	1291	+	7
	1292	+	8
	1293	+	9
	1294	+	10
	1295	+	11
	1296	+	12
	1297	+	13
	1298	+	14
	1299	+	15
	1300	+	16
	1301	+	17
	1302	+	18
	1303	+	19
	1304	+	20
	1305	+	21
	1306	+	22
	1307	+	23
	1308	+	24
	1309	+
1063	1310		halophenyl group, whethe r or not substituted at the carboxamide
1064	1311		group by an adamantyl, naphthyl, phenyl , benzyl, quinolinyl,
1065	1312		cycloalkyl, 1-amino-3-methyl-1-oxobutan-2-yl, 1-amino-3,3-dimethyl-
1066	1313		1-oxobutan-2-yl, 1-methoxy-3-methyl-1-oxobutan-2-yl, 1-methoxy-3,3-
1067	1314		dimethyl-1-oxobutan-2-yl or pyrrole group, and whether or not
1068	1315		further substituted in the indole, ada mantyl, naphthyl, phenyl,
1069	1316		pyrrole, quninolinyl, or cycloalkyl rings to any extent . Indole
1070	1317		Amides include, but are not limited to:
1071		-
1072	1318		a. N-(1-adamantyl)-1-pentyl-1H-indole-3-carboxamide
1073	1319		(2NE1),
1074		-
1075	1320		b. N-(1-adamantyl)-1-(5-fluoropentyl-1H-indole-3-
1076	1321		carboxamide (STS-135),
1077		-
1078	1322		c. N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-pentyl-1H-
1079	1323		indole-3-carboxamide (ADBICA),
1080		-
1081	1324		d. N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-(5-
1082	1325		fluoropentyl)-1H-indole-3-carboxamide (5F-ADBICA),
1083		-
1084	1326		e. N-(naphthalen-1-yl)-1-pentyl-1H-indole-3-carboxamide
1085	1327		(NNE1),
1086		-
1087	1328		f. 1-(5-fluoropentyl)-N-(naphthalene-1-yl)-1H-indole-3-
1088	1329		carboxamide (5F-NNE1),
1089		-
1090	1330		g. N-benzyl-1-pentyl-1H-indole-3-carboxamide (SDB-006),
1091	1331		or
1092		-
1093	1332		h. N-benzyl-1-(5-fluoropentyl)-1H-indole-3-carboxamide
1094	1333		(5F-SDB-006);
	1334	+
	1335	+	SB1152 HFLR Page 27
	1336	+	BOLD FACE denotes Committee Amendments. 1
	1337	+	2
	1338	+	3
	1339	+	4
	1340	+	5
	1341	+	6
	1342	+	7
	1343	+	8
	1344	+	9
	1345	+	10
	1346	+	11
	1347	+	12
	1348	+	13
	1349	+	14
	1350	+	15
	1351	+	16
	1352	+	17
	1353	+	18
	1354	+	19
	1355	+	20
	1356	+	21
	1357	+	22
	1358	+	23
	1359	+	24
1095	1360
1096	1361		10. Indole Esters: Any compound containing a 1 H-Indole-3-
1097	1362		carboxylate structure with or without substitution at the nitrogen
1098	1363		atom of the indole ring by an alkyl, haloalkyl, cyanoalkyl, alkenyl,
1099	1364		cycloalkylmethyl, cycloalkylet hyl, benzyl, halobenzyl, 1 -(N-methyl-
1100	1365		2-piperidinyl)methyl, 2-(4-morpholinyl)ethyl, 1-(N-methyl-2-
1101	1366		pyrrolidinyl)methyl, 1 -(N-methyl-3-morpholinyl)methyl,
1102		-
1103		-	ENR. S. B. NO. 1152 Page 26
1104	1367		(tetrahydropyran-4-yl)methyl, 1-methylazepanyl, phenyl, or
1105	1368		halophenyl group, whet her or not substituted at the carboxylate
1106	1369		group by an adamantyl, naphthy l, phenyl, benzyl, quinolinyl,
1107	1370		cycloalkyl, 1-amino-3-methyl-1-oxobutan-2-yl, 1-amino-3,3-dimethyl-
1108	1371		1-oxobutan-2-yl, 1-methoxy-3-methyl-1-oxobutan-2-yl, 1-methoxy-3,3-
1109	1372		dimethyl-1-oxobutan-2-yl or pyrrole group, and whether or not
1110	1373		further substituted in the in dole, adamantyl, naphthyl, phe nyl,
1111	1374		pyrrole, quinolinyl, or cycloalkyl rings to any extent . Indole
1112	1375		Esters include, but are not limited to:
1113		-
1114	1376		a. quinolin-8-yl 1-pentyl-1H-indole-3-carboxylate (PB-
1115	1377		22),
1116		-
1117	1378		b. quinolin-8-yl 1-(5-fluoropentyl)-1H-indole-3-
1118	1379		carboxylate (5F-PB-22),
1119		-
1120	1380		c. quinolin-8-yl 1-(cyclohexylmethyl)-1H-indole-3-
1121	1381		carboxylate (BB-22),
1122		-
1123	1382		d. naphthalen-1-yl 1-(4-fluorobenzyl)-1H-indole-3-
1124	1383		carboxylate (FDU-PB-22), or
1125	1384
	1385	+	SB1152 HFLR Page 28
	1386	+	BOLD FACE denotes Committee Amendments. 1
	1387	+	2
	1388	+	3
	1389	+	4
	1390	+	5
	1391	+	6
	1392	+	7
	1393	+	8
	1394	+	9
	1395	+	10
	1396	+	11
	1397	+	12
	1398	+	13
	1399	+	14
	1400	+	15
	1401	+	16
	1402	+	17
	1403	+	18
	1404	+	19
	1405	+	20
	1406	+	21
	1407	+	22
	1408	+	23
	1409	+	24
	1410	+
1126	1411		e. naphthalen-1-yl 1-(5-fluoropentyl)-1H-indole-3-
1127	1412		carboxylate (NM2201);
1128		-
1129	1413		11. Adamantanoylindoles: Any compound containing an
1130	1414		adamantanyl-(1H-indol-3-yl)methanone structure with or without
1131	1415		substitution at the ni trogen atom of the indole ring by an alkyl,
1132	1416		haloalkyl, cyanoalkyl, alkenyl, cycloalkylmet hyl, cycloalkylethyl,
1133	1417		benzyl, halobenzyl, 1 -(N-methyl-2-piperidinyl)methyl, 2 -(4-
1134	1418		morpholinyl)ethyl, 1-(N-methyl-2-pyrrolidinyl)methyl, 1 -(N-methyl-3-
1135	1419		morpholinyl)methyl, (tetrahydropyran-4-yl)methyl, 1-methylazepanyl,
1136	1420		phenyl, or halophenyl group, whether o r not further substituted in
1137	1421		the indole ring to any extent and whether or not s ubstituted in the
1138	1422		adamantyl ring to any extent . Adamantanoylindoles include, but are
1139	1423		not limited to:
1140		-
1141	1424		a. adamantan-1-yl[1-[(1-methyl-2-piperidinyl)methyl]-1H-
1142	1425		indol-3-yl]methanone (AM1248), or
1143		-
1144	1426		b. adamantan-1-yl-(1-pentyl-1H-indol-3-yl)methanone (AB-
1145	1427		001);
1146		-
1147		-	ENR. S. B. NO. 1152 Page 27
1148		-
1149	1428		12. Carbazole Ketone: Any compound containing (9H -carbazole-3-
1150	1429		yl) methanone structure wi th or without substitution at the nitrogen
1151	1430		atom of the carbazole r ing by an alkyl, haloal kyl, cyanoalkyl,
1152	1431		alkenyl, cycloalkylmeth yl, cycloalkylethyl, benzyl, halobenzyl , 1-
1153	1432		(N-methyl-2-piperidinyl)methyl, 2-(4-morpholinyl)ethyl, 1 -(N-methyl-
1154	1433		2-pyrrolidinyl)methyl, 1-(N-methyl-3-morpholinyl)methyl,
1155	1434		(tetrahydropyran-4-yl)methyl, 1-methylazepanyl, phenyl, or
	1435	+
	1436	+	SB1152 HFLR Page 29
	1437	+	BOLD FACE denotes Committee Amendments. 1
	1438	+	2
	1439	+	3
	1440	+	4
	1441	+	5
	1442	+	6
	1443	+	7
	1444	+	8
	1445	+	9
	1446	+	10
	1447	+	11
	1448	+	12
	1449	+	13
	1450	+	14
	1451	+	15
	1452	+	16
	1453	+	17
	1454	+	18
	1455	+	19
	1456	+	20
	1457	+	21
	1458	+	22
	1459	+	23
	1460	+	24
	1461	+
1156	1462		halophenyl group, with substi tution at the carbon of the methanone
1157	1463		group by an adamantyl, naphthyl, phenyl, benzyl, quinolinyl,
1158	1464		cycloalkyl, 1-amino-3-methyl-1-oxobutan-2-yl, 1-amino-3,3-dimethyl-
1159	1465		1-oxobutan-2-yl, 1-methoxy-3-methyl-1-oxobutan-2-yl, 1-methoxy-3,3-
1160	1466		dimethyl-1-oxobutan-2-yl or pyrrole group, and whether or not
1161	1467		further substituted at the carbazole, adamantyl, naphthyl, phenyl,
1162	1468		pyrrole, quinolinyl, or cycloalkyl rings to any extent. Carbazole
1163	1469		Ketones include, but are not limited to, na phthalen-1-yl(9-pentyl-
1164	1470		9H-carbazol-3-yl)methanone (EG-018);
1165		-
1166	1471		13. Benzimidazole Ketone: Any compound containing
1167	1472		(benzimidazole-2-yl) methanone structure with or withou t
1168	1473		substitution at either nitrogen atom of the benzimidazole ring b y an
1169	1474		alkyl, haloalkyl, cyanoalkyl, alkenyl, cycloalkylmethyl,
1170	1475		cycloalkylethyl, benzyl, halobenzyl, 1 -(N-methyl-2-
1171	1476		piperidinyl)methyl, 2-(4-morpholinyl)ethyl, 1 -(N-methyl-2-
1172	1477		pyrrolidinyl)methyl, 1-(N-methyl-3-morpholinyl)methyl,
1173	1478		(tetrahydropyran-4-yl)methyl, 1-methylazepanyl, pheny l, or
1174	1479		halophenyl group, with substituti on at the carbon of the methanone
1175	1480		group by an adamantyl, naphthyl, phenyl, benzyl, quinolinyl,
1176	1481		cycloalkyl, 1-amino-3-methyl-1-oxobutan-2-yl, 1-amino-3,3-dimethyl-
1177	1482		1-oxobutan-2-yl, 1-methoxy-3-methyl-1-oxobutan-2-yl, 1-methoxy-3,3-
1178	1483		dimethyl-1-oxobutan-2-yl or pyrrole group, and whether or not
1179	1484		further substituted in the benzimidazole, adamantyl, naphthyl,
	1485	+
	1486	+	SB1152 HFLR Page 30
	1487	+	BOLD FACE denotes Committee Amendments. 1
	1488	+	2
	1489	+	3
	1490	+	4
	1491	+	5
	1492	+	6
	1493	+	7
	1494	+	8
	1495	+	9
	1496	+	10
	1497	+	11
	1498	+	12
	1499	+	13
	1500	+	14
	1501	+	15
	1502	+	16
	1503	+	17
	1504	+	18
	1505	+	19
	1506	+	20
	1507	+	21
	1508	+	22
	1509	+	23
	1510	+	24
	1511	+
1180	1512		phenyl, pyrrole, quinolinyl, o r cycloalkyl rings to any extent.
1181	1513		Benzimidazole Ketones include, but are not limited to:
1182		-
1183	1514		a. naphthalen-1-yl(1-pentyl-1H-benzo[d]imidazol-2-
1184	1515		l)methanone (JWH-018 benzimidazole analog), or
1185		-
1186	1516		b. (1-(5-fluoropentyl)-1H-benzo[d]imidazol-2-
1187	1517		yl)(naphthalen-1-yl)methanone (FUBIMINA); and
1188		-
1189		-
1190		-	ENR. S. B. NO. 1152 Page 28
1191	1518		14. Modified by Replacement : any compound defined in this
1192	1519		subsection that is modified by replacement of a carbon with nitrogen
1193	1520		in the indole, naphthyl, indene, benzimidazole, or carbazole ring.
1194		-
1195	1521		H. Any prescription drug approved by the federal Food and Drug
1196	1522		Administration under the pr ovisions of Section 505 of the Federal
1197	1523		Food, Drug and Cosmetic Act , Title 21 of the United States Code,
1198	1524		Section 355, that is designated, rescheduled or del eted as a
1199	1525		controlled substance under federal law by the United States Drug
1200	1526		Enforcement Administration shall be exc luded from Schedule I a nd
1201	1527		shall be prescribed, distributed , dispensed or used in accordance
1202	1528		with federal law upon the issuance of a notice, final rule or
1203	1529		interim final rule by the United Sta tes Drug Enforcement
1204	1530		Administration designating, rescheduling or deleting as a controlled
1205	1531		substance such a drug product unde r federal law, unless and until
1206	1532		the Board of Pharmacy takes action pursuant to Section 2 -201 of this
1207	1533		title. If the Board of Pharmac y does not take action pursuant to
1208	1534		Section 2-201 of this title, the drug product shall be deemed to be
1209	1535		designated, reschedul ed or deleted as a controlled substance in
	1536	+
	1537	+	SB1152 HFLR Page 31
	1538	+	BOLD FACE denotes Committee Amendments. 1
	1539	+	2
	1540	+	3
	1541	+	4
	1542	+	5
	1543	+	6
	1544	+	7
	1545	+	8
	1546	+	9
	1547	+	10
	1548	+	11
	1549	+	12
	1550	+	13
	1551	+	14
	1552	+	15
	1553	+	16
	1554	+	17
	1555	+	18
	1556	+	19
	1557	+	20
	1558	+	21
	1559	+	22
	1560	+	23
	1561	+	24
	1562	+
1210	1563		accordance with federal law and in compliance with the Uniform
1211	1564		Controlled Dangerous Subst ances Act.
1212		-
1213	1565		SECTION 2. This act shall become effective November 1, 2022.
1214	1566
1215		-
1216		-	ENR. S. B. NO. 1152 Page 29
1217		-	Passed the Senate the 28th day of February, 2022.
1218		-
1219		-
1220		-
1221		-	Presiding Officer of the Senate
1222		-
1223		-
1224		-	Passed the House of Representatives the 20th day of April, 2022.
1225		-
1226		-
1227		-
1228		-	Presiding Officer of the House
1229		-	of Representatives
1230		-
1231		-	OFFICE OF THE GOVERNOR
1232		-	Received by the Office of the Governor this _______ _____________
1233		-	day of _________________ __, 20_______, at _______ o'clock _______ M.
1234		-	By: _______________________________ __
1235		-	Approved by the Governor of the State of Oklah oma this _________
1236		-	day of _________________ __, 20_______, at _______ o'clock _______ M.
1237		-
1238		-	_________________________________
1239		-	Governor of the State of Oklahoma
1240		-
1241		-
1242		-	OFFICE OF THE SECRETARY OF STATE
1243		-	Received by the Office of the Secretary of State this _______ ___
1244		-	day of __________________, 20 _______, at _______ o'clock _______ M.
1245		-	By: _______________________________ __
	1567	+	COMMITTEE REPORT BY: COMMITTEE ON ALCOHOL, TOBACCO AND CONTROLLED
	1568	+	SUBSTANCES, dated 04/14/2022 - DO PASS.